Recruitment complete for Phase II prostate cancer trial

Sydney, Australia 7 June 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the completion of recruitment for the Phase II investigator initiated diagnostic trial, BOP (NCT05613842)1, evaluating its 64Cu-SAR-Bombesin product…

Oncology Expert Joins Clarity as Senior Medical Director

Sydney, Australia 2 May 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of Dr Othon Gervasio as Senior Medical Director, effective immediately. Dr Gervasio is an experienced senior leader with…

Clarity Receives $6.7 million R&D Tax Incentive Refund

Sydney, Australia 18 April 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that it has received a $6,726,900 Research and Development (R&D) Tax Incentive refund as part of the Australian Federal Government’s…

US based COBRA diagnostic prostate cancer trial reaches recruitment target

Sydney, Australia 9 February 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-bisPSMA trial COBRA (NCT05249127)1 for patients with prostate cancer has reached its recruitment target. COBRA (Copper-64 SAR-bisPSMA in Biochemically Recurrent prostAte…

Clarity update on NorthStar copper-67 production

Sydney, Australia 4 April 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to provide an update on copper-67 (Cu-67 or 67Cu) production by NorthStar Medical Radioisotopes, LLC (NorthStar). NorthStar, a global innovator in the…

World leading expert in copper-67 joins Clarity’s SAB

Sydney, Australia 1 March 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of the world leading expert in copper-67 isotope (Cu-67 or 67Cu) production, Jon Stoner, to Clarity’s Scientific Advisory…

Clarity reaches 50% recruitment milestone for DISCO neuroendocrine tumour diagnostic Phase II trial

Sydney, Australia 16 February 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its Phase II diagnostic 64Cu SARTATE trial (DISCO NCT044383041) for patients with known or suspected neuroendocrine tumours (NETs) has reached the…

PROPELLER Trial Results – SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer

Sydney, Australia 14 February 2023 Highlights PROPELLER trial achieved all primary and secondary objectives 64Cu SAR-bisPSMA was safe and well tolerated by trial participants Uptake of Clarity’s 64Cu SAR-bisPSMA in cancer lesions is higher compared to the approved standard-of-care for prostate cancer imaging in Australia and the US, 68Ga PSMA-11 Greater uptake into cancer lesions…

Clarity confirms no supply interruptions to its ongoing clinical trials programs

Sydney, Australia 2 March 2023   Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, notes the recent supply interruption for Novartis’ Pluvicto™ radiotherapy to patients1-2 and confirms Clarity’s Targeted Copper Theranostics (TCTs) products and clinical development programs are…